Insulin degludec as an ultralong-acting basal insulin once a day: a systematic review

References

• Kurtzhals P How to achieve a predictable basal insulin? Diabetes Metab 2005 31 4 Pt 2 4S25 24S33 16389895
   PubMed Web of Science ®Google Scholar
• Rosenstock J Dailey G Massi-Benedetti M Fritsche A Lin Z Salzman A Reduced hypoglycemia risk with insulin glargine: a meta-analysis comparing insulin glargine with human NPH insulin in type 2 diabetes Diabetes Care 2005 28 4 950 955 15793205
   PubMed Web of Science ®Google Scholar
• Haak T Tiengo A Draeger E Suntum M Waldhäusl W Lower within subject variability of fasting blood glucose and reduced weight gain with insulin detemir compared to NPH insulin in patients with type 2 diabetes Diabetes Obes Metab 2005 7 1 56 64 15642076
   PubMed Web of Science ®Google Scholar
• De Leeuw I Vague P Selam JL Insulin detemir used in basal bolus therapy in people with type 1 diabetes is associated with a lower risk of nocturnal hypoglycaemia and less weight gain over 12 months in comparison to NPH insulin Diabetes Obes Metab 2005 7 1 73 82 15642078
   PubMed Web of Science ®Google Scholar
• Vague P Selam JL Skeie S Insulin detemir is associated with more predictable glycemic control and reduced risk of hypoglycemia than NPH insulin in patients with type 1 diabetes on a basal-bolus regimen with premeal insulin aspart Diabetes Care 2003 26 3 590 596 12610006
   PubMed Web of Science ®Google Scholar
• Ratner RE Hirsch IB Neifing JL Garg SK Mecca TE Wilson CA Less hypoglycemia with insulin glargine in intensive insulin therapy for type 1 diabetes. US Study Group of Insulin Glargine in Type 1 Diabetes Diabetes Care 2000 23 5 639 643 10834423
   PubMed Web of Science ®Google Scholar
• Yki-Järvinen H Dressler A Ziemen M HOE 901/300s Study Group Less nocturnal hypoglycemia and better post-dinner glucose control with bedtime insulin glargine compared with bedtime NPH insulin during insulin combination therapy in type 2 diabetes. HOE 901/3002 study group Diabetes Care 2000 23 8 1130 1136 10937510
   PubMed Web of Science ®Google Scholar
• Davies MJ Derezinski T Pedersen CB Clauson P Reduced weight gain with insulin detemir compared to NPH insulin is not explained by a reduction in hypoglycemia Diabetes Technol Ther 2008 10 4 273 277 18715200
   PubMed Web of Science ®Google Scholar
• Raslová K Tamer SC Clauson P Karl D Insulin detemir results in less weight gain than NPH insulin when used in basal-bolus therapy for type 2 diabetes mellitus, and this advantage increases with baseline body mass index Clin Drug Investig 2007 27 4 279 285
   PubMed Web of Science ®Google Scholar
• Hollander P Cooper J Bregnhoj J Pederson CB A 52-week, multinational, open-label, parallel-group, noninferiority, treat-to-target trial comparing insulin detemir with insulin glargine in a basal-bolus regimen with mealtime insulin aspart in patients with type 2 diabetes Clin Ther 2008 30 11 1976 1987 19108786
   PubMed Web of Science ®Google Scholar
• Rosenstock J Davies M Home PD Larsen J Koenen C Schernthaner G A randomized, 52-week, treat-to-target trial comparing insulin detemir with insulin glargine when administered as add-on to glucose-lowering drugs in insulin naïve people with type 2 diabetes Diabetologia 2008 51 3 408 416 18204830
   PubMed Web of Science ®Google Scholar
• Raskin P Gylvin T Weng W Chaykin L Comparison of insulin detemir and insulin glargine using a basal-bolus regimen in a randomized, controlled clinical study in patients with type 2 diabetes Diabetes Metab Res Rev 2009 25 6 542 548 19565569
   PubMed Web of Science ®Google Scholar
• Blonde L Merilainen M Karwe V Raskin P TITRATE Study Group Patient-directed titration for achieving glycaemic goals using a once-daily basal insulin analogue: an assessment of two different fasting plasma glucose targets – the TITRATE study Diabetes Obes Metab 2009 11 6 623 631 19515182
   PubMed Web of Science ®Google Scholar
• Porcellati F Bolli GB Fanelli CG Pharmacokinetics and pharmacodynamics of basal insulins Diabetes Technol Ther 2011 13 Suppl 1 S15 S24 21668333
   PubMed Web of Science ®Google Scholar
• Swinnen SG Simon AC Holleman F Hoekstra JB Devries JH Insulin detemir versus insulin glargine for type 2 diabetes mellitus Cochrane Database Syst Rev 2011 7 CD006383 21735405
   PubMed Web of Science ®Google Scholar
• Kurtzhals P Heise T Strauss HM Multi-hexamer formation is the underlying mechanism behind the ultra-long glucose-lowering effect of insulin degludec Paper presented at: American Diabetes Association (ADA) 71st Scientific Session Jun 2011 San Diego, CA, USA
   Google Scholar
• Mathieu C Fulcher G Rao PV Insulin degludec, a new generation ultra-long acting insulin, used once daily or 3-times weekly in people with type 2 diabetes: Comparison to insulin glargine Diabetologia 2010 53 Suppl 1 S8
   Google Scholar
• Meneghini L Atkin SL Bain S Flexible once-daily dosing of insulin degludec does not compromise glycemic control or safety compared to insulin glargine given once daily at the same time each day in people with type 2 diabetes Paper presented at: American Diabetes Association (ADA) 71st Scientific Session Jun 2011 San Diego, CA, USA
   Google Scholar
• Birkeland KI Raz I Gough S Insulin degludec in a flexible daily dosing regimen provides similar glycaemic control without increasing rates of hypoglycaemia compared to dosing the same time daily in type 2 diabetes Paper presented at: 47th European Association for the Study of Diabetes (EASD) Annual Meeting Sep 2011 Lisbon, Portugal
   Google Scholar
• Atkin SL Bain SC Gough S Insulin degludec does not compromise efficacy or safety when given in a flexible once-daily dosing regimen compared to insulin glargine once daily at the same time each day in type 2 diabetes Paper presented at: 47th European Association for the Study of Diabetes (EASD) Annual Meeting Sep 2011 Lisbon, Portugal
   Google Scholar
• Home PD Meneghini L Ratner RE A comparison of quality of life measured with the SF-36 for insulin degludec and insulin glargine in people with type 1 diabetes Paper presented at: 47th European Association for the Study of Diabetes (EASD) Annual Meeting Sep 2011 Lisbon, Portugal
   Google Scholar
• Jonassen I Havelund S Ribel U Insulin degludec is a new generation ultra-long acting basal insulin with a unique mechanism of protraction based on multi-hexamer formation Diabetes 2010 59 Suppl 1 A11
   Google Scholar
• Jonassen I Havelund S Ribel U Insulin degludec: Multi-hexamer formation is the underlying basis for this new generation ultra-long acting basal insulin Diabetologia 2010 53 Suppl 1 S388
   Google Scholar
• Meneghini LF Miranda-Palma B Insulin degludec: A novel ultra-long-acting basal insulin for use in type 1 and 2 diabetes Expert Rev Endocrinol Metab 2012 7 1 9 14
   PubMedGoogle Scholar
• Nosek L Heise T Bøttcher SG Hastrup H Haahr H Ultra-long-acting insulin degludec has a flat and stable glucose-lowering effect Paper presented at: American Diabetes Association (ADA) 71st Scientific Session Jun 2011 San Diego, CA, USA
   Google Scholar
• Russell-Jones DL Francisco AO Pei H Heller SR Basal-bolus therapy with insulin degludec improves long-term glycaemic control with less nocturnal hypoglycaemia compared with insulin glargine in type 1 diabetes: Results of a 1-year trial Paper presented at: 47th European Association for the Study of Diabetes Meeting (EASD) Annual Meeting Sept 2011 Lisbon, Portugal
   Google Scholar
• Pieber T Korsatko S Koumlhler G Response to induced hypoglycemia in type 1 diabetes: Insulin degludec elicits an enhanced counter-regulatory hormone response compared to insulin glargine Paper presented at: American Diabetes Association (ADA) 71st Scientific Session June 2011 San Diego, CA
   Google Scholar
• Heller S Francisco AO Pei H Russell-Jones D Insulin degludec improves long-term glycemic control with less nocturnal hypoglycemia compared with insulin glargine: 1-year results from a randomized basal-bolus trial in type 1 diabetes Paper presented at: American Diabetes Association 71st Scientific Sessions Jun 2011 San Diego, CA
   Google Scholar
• Birkeland KI Home PD Wendisch U Insulin degludec in type 1 diabetes: a randomized controlled trial of a new-generation ultra-long-acting insulin compared with insulin glargine Diabetes Care 2011 34 3 661 665 21270174
   PubMed Web of Science ®Google Scholar
• Meneghini LF Home PD Wendisch U Insulin degludec, a new generation ultra-long acting insulin, in a mealtime + basal regimen in people with type 1 diabetes: Comparison to insulin glargine Diabetologia 2010 53 Suppl 1 S381
   Google Scholar
• Cuddihy R Tack CJ Heise T Once-daily use of a new generation ultra-long acting basal insulin with a bolus boost in insulin-naive people with type 2 diabetes: Comparison with insulin glargine Diabetologia 2010 53 Suppl 1 S389
   Google Scholar
• Hollander PA King AB Francisco AO Endahl L Garber A Basal-bolus therapy with insulin degludec improves long-term glycaemic control with fewer nocturnal hypoglycaemic events compared with insulin glargine in people with type 2 diabetes Paper presented at: 47th European Association for the Study of Diabetes (EASD) Annual Meeting Sep 2011 Lisbon, Portugal
   Google Scholar
• Garber AJ King AB Francisco AO Endahl L Hollander PA Insulin degludec improves long-term glycemic control with less nocturnal hypoglycemia compared with insulin glargine: 1-year results from a randomized basal-bolus trial in people with type 2 diabetes Paper presented at: American Diabetes Association (ADA) 71st Scientific Sessions Jun 2011 San Diego, CA
   Google Scholar
• Zinman B Fulcher G Rao PV Insulin degludec, an ultra-long-acting basal insulin, once a day or three times a week versus insulin glargine once a day in patients with type 2 diabetes: a 16-week, randomised, open-label, phase 2 trial Lancet 2011 377 9769 924 931 21396703
   PubMed Web of Science ®Google Scholar
• Heise T Hermanski L Nosek I Insulin degludec: Less pharmacodynamic variability than insulin glargine under steady state conditions Diabetologia 2010 53 Suppl 1 S387
   Google Scholar
• Hirsch I Franek E Courrèges JP Mersebach H Dykiel P Bode BW IDegAsp, a soluble insulin combination of ultra-long-acting insulin degludec and insulin aspart, used once-daily in basal-bolus treatment with insulin aspart in type 1 diabetes Paper presented at: 47th European Association for the Study of Diabetes (EASD) Annual Meeting Sep 2011 Lisbon, Portugal
   Google Scholar
• Hirsch IB Franek E Courreges J Mersebach H Dykiel P Bode BW Efficacy and safety of a new basal insulin with a bolus boost (IDegAsp) used once daily in combination with insulin aspart (IAsp) in people with type 1 diabetes Paper presented at: American Diabetes Association 71st Scientific Sessions Jun 2011 San Diego, CA
   Google Scholar
• Heise T Tack CJ Cuddihy R A new-generation ultra-long-acting basal insulin with a bolus boost compared with insulin glargine in insulin-naive people with type 2 diabetes: a randomized, controlled trial Diabetes Care 2011 34 3 669 674 21285389
   PubMed Web of Science ®Google Scholar
• Heller SR Pieber TR Korsatko S A higher counter-regulatory hormone response is seen with insulin degludec than insulin glargine in response to induced hypoglycaemia in type 1 diabetes Paper presented at: 47th European Association for the Study of Diabetes (EASD) Annual Meeting Sep 2011 Lisbon, Portugal
   Google Scholar
• Jonassen I Hoeg-Jensen T Havelund S Ribel U Ultra-long acting insulin degludec can be combined with rapid-acting insulin aspart in a soluble co-formulation J Pept Sci 2010 16 Suppl 1 32
   Google Scholar
• Vaag A Leiter LA Franek E Use of a new basal insulin with a bolus boost (IDegAsp) in type 2 diabetes: Comparison with biphasic insulin aspart 30 (BIAsp 30) Paper presented at: American Diabetes Association (ADA) 71st Scientific Session Jun 2011 San Diego, CA
   Google Scholar
• Korsatko S Deller S Zahiragic S Ultra-long-acting insulin degludec: Bio-equivalence and similar pharmacodynamics shown for two different formulations (U100 and U200) Paper presented at: 47th European Association for the Study of Diabetes Meeting (EASD) Annual Meeting Sep 2011 Lisbon, Portugal
   Google Scholar
• Heise T Hövelmann U Nosek L Bøttcher SG Granhall C Haahr H Insulin degludec has a two-fold longer half-life and a more consistent pharmacokinetic profile than insulin glargine Paper presented at: American Diabetes Association 71st Scientific Sessions Jun 2011 San Diego, CA
   Google Scholar
• Heise T Hermanski L Nosek L Feldmann A Rasmussen S Haahr H The pharmacodynamic variability of insulin degludec is consistently lower than insulin glargine over 24 hours at steady state Paper presented at: American Diabetes Association 71st Scientific Sessions June 2011 San Diego, CA
   Google Scholar
• Danne T Biester T Blaesig S The pharmacokinetic properties of insulin degludec in children and adolescents compared with adults with type 1 diabetes after single-dose administration Pediatric Diabetes 2011 12 Suppl 15 35 36
   Google Scholar
• ClinicalTrials.gov Investigating the Pharmacokinetic Properties of NN1250 in Healthy Chinese Subjects [updated 2011 November 28]. Available at: http://clinicaltrials.gov/show/NCT01437592 Accessed December 30, 2011
   Google Scholar
• Meneghini LF Home PD Wendisch U Insulin degludec, a new generation ultra-long acting insulin, in a mealtime plus basal regimen in people with type 1 diabetes: Comparison to insulin glargine Diabetes 2010 59 Suppl 1 A152
   Google Scholar
• Home PD Meneghini L Wendisch U Improved health status with insulin degludec compared with insulin glargine in people with type 1 diabetes Diabet Med 2011 10.1111/j.1464–5491.2011.03547.x
   Web of Science ®Google Scholar
• Vaag LA Leiter E Franek J IDegAsp, a soluble insulin combination of ultra-long acting insulin degludec and insulin aspart, in type 2 diabetes: Comparison with biphasic insulin aspart 30 Paper presented at: 47th European Association for the Study of Diabetes Meeting (EASD) Annual Meeting Sep 2011 Lisbon, Portugal
   Google Scholar
• Bain S Atkin S Gough S Flexible once-daily dosing of insulin degludec is as efficacious and safe as insulin glargine given the same time each day in type 2 diabetes Paper presented at: World Diabetes Congress (International Diabetes Federation) Dec 2011 Dubai
   Google Scholar
• Niskanen L Leiter LA Franek E IDegAsp, a soluble insulin combination of insulin degludec and insulin aspart, in type 2 diabetes: Comparison to biphasic insulin aspart 30 Paper presented at: World Diabetes Congress (International Diabetes Federation) Dec 2011 Dubai
   Google Scholar
• Clinical Trials at Novo Nordisk [homepage on the Internet]. Available at: HYPERLINK http://www.novonordisk-trials.com/t_blank www.novonordisk-trials.com Accessed January 14, 2012
   Google Scholar
• Vigneri R Squatrito S Sciacca L Insulin and its analogs: actions via insulin and IGF receptors Acta Diabetol 2010 47 4 271 278 20730455
   PubMed Web of Science ®Google Scholar
• Weinstein D Simon M Yehezkel E Laron Z Werner H Insulin analogues display IGF-I-like mitogenic and anti-apoptotic activities in cultured cancer cells Diabetes Metab Res Rev 2009 25 1 41 49 19145584
   PubMed Web of Science ®Google Scholar
• Kurtzhals P Schäffer L Sørensen A Correlations of receptor binding and metabolic and mitogenic potencies of insulin analogs designed for clinical use Diabetes 2000 49 6 999 1005 10866053
   PubMed Web of Science ®Google Scholar
• Dejgaard A Lynggaard H Råstam J Krogsgaard Thomsen M No evidence of increased risk of malignancies in patients with diabetes treated with insulin detemir: a meta-analysis Diabetologia 2009 52 12 2507 2512 19838665
   PubMed Web of Science ®Google Scholar
• Kellerer M Häring H Insulin analogues: impact of cell model characteristics on results and conclusions regarding mitogenic properties Exp Clinl Endocrinol Diabetes 2001 109 1 63 64
   Web of Science ®Google Scholar
• Wang F Carabino JM Vergara CM Insulin glargine: a systematic review of a long-acting insulin analogue Clin Ther 2003 25 6 1541 1577 discussion 1539–1540 12860485
   PubMed Web of Science ®Google Scholar
• Ciaraldi TP Sasaoka T Review on the in vitro interaction of insulin glargine with the insulin/insulin-like growth factor system: potential implications for metabolic and mitogenic activities Horm Metab Res 2011 43 1 1 10 20938889
   PubMed Web of Science ®Google Scholar
• Hemkens LG Grouven U Bender R Risk of malignancies in patients with diabetes treated with human insulin or insulin analogues: a cohort study Diabetologia 2009 52 9 1732 1744 19565214
   PubMed Web of Science ®Google Scholar
• Colhoun HM SDRN Epidemiology Group Use of insulin glargine and cancer incidence in Scotland: a study from the Scottish Diabetes Research Network Epidemiology Group Diabetologia 2009 52 9 1755 1765 19603149
   PubMed Web of Science ®Google Scholar
• Jonasson JM Ljung R Talbäck M Haglund B Gudbjörnsdòttir S Steineck G Insulin glargine use and short-term incidence of malignancies – a population-based follow-up study in Sweden Diabetologia 2009 52 9 1745 1754 19588120
   PubMed Web of Science ®Google Scholar
• Mannucci E Monami M Balzi D Doses of insulin and its analogues and cancer occurrence in insulin-treated type 2 diabetic patients Diabetes Care 2010 33 9 1997 2003 20551014
   PubMed Web of Science ®Google Scholar
• US Food and Drug Administration FDA Drug Safety Communication: Update to ongoing safety review of Lantus (insulin glargine) and possible risk of cancer [updated 2011 January 20]. Available at: http://www.fda.gov/Drugs/DrugSafety/ucm239376.htm Accessed March 17, 2012
   Google Scholar
• Simon AC DeVries JH The future of basal insulin supplementation Diabetes Technol Ther 2011 13 Suppl 1 S103 S108 21568722
   PubMed Web of Science ®Google Scholar
• Nishimura E Sorensen AR Hansen BF Insulin degludec: A new ultra-long, basal insulin designed to maintain full metabolic effect while minimizing mitogenic potential Diabetologia 2010 53 Suppl 1 S388
   Google Scholar
• Nishimura E Sorensen A Hansen BF Insulin degludec is a new generation ultra-long acting basal insulin designed to maintain full metabolic effect while minimizing mitogenic potential Diabetes 2010 59 Suppl 1 A375
   Google Scholar
• Ahrén B Burke B Using albumin to improve the therapeutic properties of diabetes treatments Diabetes Obes Metab 2012 14 2 121 129 21812895
   PubMed Web of Science ®Google Scholar